Cosentyx vs Humira
Side-by-side cost comparison based on Medicare Part D data
Cosentyx
Secukinumab
Manufactured by Novartis
Humira
Adalimumab
Manufactured by AbbVie
Humira costs 6% less per claim than Cosentyx ($3,414.00 vs $3,616.00). A generic version of Humira is also available, which may reduce costs further.
Cost Per Claim
Medicare Spending
Beneficiaries
Annual Cost Per Patient
Full Comparison
| Metric | Cosentyx | Humira |
|---|---|---|
| Avg Cost Per Claim | $3,616.00 | $3,414.00 |
| Total Medicare Spending | $3.1B | $6.5B |
| Total Beneficiaries | 120,000 | 195,000 |
| Total Claims | 864,000 | 1,890,000 |
| Annual Cost/Patient | $26,033.00 | $33,092.00 |
| Year-over-Year Change | +8.9% | -22.1% |
| Generic Available | Yes | Yes |
| Patent Expiration | Jan 31, 2023 | Jan 31, 2023 |
| Manufacturer | Novartis | AbbVie |
| Condition | Autoimmune Diseases | Autoimmune Diseases |
| Generic Name | Secukinumab | Adalimumab |
Cosentyx vs Humira: What the Data Shows
Cosentyx (Secukinumab) and Humira (Adalimumab) are both used to treat autoimmune diseases. Based on Medicare Part D data, Humira costs $3,414.00 per claim, which is 6% less than Cosentyx at $3,616.00 per claim.
Medicare spent $3.1B on Cosentyx and $6.5B on Humira. In terms of patient reach, Humira serves more beneficiaries (195,000 vs 120,000).
Year-over-year spending changed +8.9% for Cosentyx and -22.1% for Humira.
Both drugs have generic versions available. Patients should discuss generic alternatives with their pharmacist to reduce out-of-pocket costs.
Frequently Asked Questions
Humira is cheaper at $3,414.00 per claim, compared to $3,616.00 for Cosentyx. That makes Humira about 6% less expensive per claim based on Medicare Part D data.
Yes, both Cosentyx and Humira are used to treat autoimmune diseases. Your doctor can help determine which medication is more appropriate for your specific situation.
Both drugs have generic versions available. Generic Secukinumab and generic Adalimumab can offer significant cost savings — typically 80-95% less than the brand name.
Medicare Part D spent $3.1B on Cosentyx covering 120,000 beneficiaries, and $6.5B on Humira covering 195,000 beneficiaries.
Explore Further
Cost data reflects Medicare Part D spending and may not represent retail pharmacy prices. Average cost per claim represents the total drug cost (not patient out-of-pocket) divided by total claims. This comparison is informational only and should not replace medical advice.